Major pathologic response predicts survival in resectable stage IIIA non-small cell lung cancer after neoadjuvant therapy.

导出 LinkOut

翻译打印收藏纠错

作者： Shihong,Zhou ^[1] ; Ying,Zhang ^[2] ; Ziheng,Wu ^[1] ; Pinghui,Xia ^[1] ; Tianyu,He ^[1] ; Jinlin,Cao ^[1] ; Wang,Lv ^[1] ; Jian,Hu ^[3]

作者单位： Department of Thoracic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ^[1] Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China. ^[2] Department of Thoracic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.;Key Laboratory of Clinical Evaluation Technology for Medical Device of Zhejiang Province, Hangzhou, China. ^[3]

关键词 long-term prognosis major pathologic response neoadjuvant chemotherapy neoadjuvant immunochemotherapy non-small cell lung cancer real-world retrospective study

DOI 10.1093/icvts/ivae213

PMID 39680899

发布时间 2025-01-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Interdisciplinary cardiovascular and thoracic surgery

2024年40卷1期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Major pathologic response predicts survival in resectable stage IIIA non-small cell lung cancer after neoadjuvant therapy.

Interdisciplinary cardiovascular and thoracic surgery

相似文献

Interdisciplinary cardiovascular and thoracic surgery

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Major pathologic response predicts survival in resectable stage IIIA non-small cell lung cancer after neoadjuvant therapy.

Interdisciplinary cardiovascular and thoracic surgery

相似文献

Interdisciplinary cardiovascular and thoracic surgery

相关期刊

检索历史清除